Ovid Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $132 | $6,272 | $130 | $76 |
Gross Profit | 115 | 6,272 | 130 | 76 |
EBITDA | -12,141 | -4,974 | -12,409 | -10,762 |
EBIT | -12,158 | -5,073 | -12,550 | -10,922 |
Net Income | -12,158 | -4,684 | -10,235 | -9,253 |
Net Change In Cash | 132 | 6,272 | 130 | 76 |
Free Cash Flow | -12,872 | -4,774 | -10,280 | -10,030 |
Cash | 20,611 | 28,415 | 21,136 | 26,301 |
Basic Shares | 71,109 | 71,109 | 71,045 | 71,010 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $566 | $392 | $1,502 | $208,382 |
Gross Profit | 566 | 392 | 1,502 | 208,382 |
EBITDA | -57,772 | -57,013 | -54,166 | 124,447 |
EBIT | -58,385 | -57,581 | -55,548 | 124,210 |
Net Income | -26,433 | -52,339 | -51,408 | 122,834 |
Net Change In Cash | 566 | 392 | 1,502 | 208,382 |
Cost of Revenue | -142,929 | 117,694 | ||
Free Cash Flow | -56,027 | -45,918 | -56,645 | 118,427 |
Cash | 26,301 | 27,042 | 44,867 | 187,797 |
Basic Shares | 70,905 | 70,581 | 70,425 | 68,068 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $0 |
2025-09-30 | -$0.17 |
2025-06-30 | -$0.06 |
2025-03-31 | -$0.14 |
